Monoclonal antibodies can block a key immune-related protein that drives the spread of brain cell damage in Parkinson's ...

Researchers identify GPNMB as a driver of Parkinson’s disease spread and demonstrate that monoclonal antibodies can block its activity to slow neurodegeneration.

Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage Parkinson’s disease. Roche has a licensing agreement with Prothena PRTA for ...

Symptoms of Parkinson’s disease can affect your daily life and well-being. Nourianz (istradefylline) is a medicine used to reduce “off” time in people with Parkinson’s disease who are taking daily ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab, ...

The startup, Cellular Intelligence, is gaining rights to the early-stage treatment and will be in charge of shepherding it ...

Long before the telltale signs of Parkinson's disease appear, including tremors and muscle stiffness, there are other, more ...

- Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s disease - - Prasinezumab is a potential ...